ArticleOncoTargets and therapy2025

Combination of Aumolertinib, Dabrafenib, and Trametinib for a Patient with Advanced Lung Adenocarcinoma with an Osimertinib-Induced BRAF V600E Mutation: A Case Report.

Diming Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.